Anti-vascular endothelial growth factor for proliferative diabetic retinopathy (Q24236189)

inferred from title

author

Arturo J Martí-Carvajal

2

0 references

Ivan Solà

Maria José Martinez-Zapata

3

0 references

1

0 references

author name string

José I Pijoán

4

0 references

José A Buil-Calvo

Cochrane Database of Systematic Reviews

5

0 references

publication date

8 September 2010

0 references

published in

0 references

cites work

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Manipulating angiogenesis in medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Effect of pregnancy on progression of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Blood pressure control and diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes : the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Intravitreal triamcinolone for refractory diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Complications in patients after intravitreal injection of bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

7 January 2021

The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

7 January 2021

Photocoagulation for Diabetic Macular Edema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

7 January 2021

Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

7 January 2021

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

7 January 2021

Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

7 January 2021

A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

7 January 2021

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

7 January 2021

Photocoagulation Treatment of Proliferative Diabetic Retinopathy: The Second Report of Diabetic Retinopathy Study Findings

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

7 January 2021

Ten-year incidence of visual loss in a diabetic population

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

7 January 2021

Cigarette smoking and ten-year progression of diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

7 January 2021

What is the prevalence of visual impairment in the general and diabetic populations: are there ethnic and gender differences?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008721

7 January 2021